-
公开(公告)号:US11564922B2
公开(公告)日:2023-01-31
申请号:US17732070
申请日:2022-04-28
Applicant: AbbVie Inc.
Inventor: Aileen L. Pangan , Roopal B. Thakkar , Steven Jungerwirth , Ana Paula Machado De Lacerda , Anne M. Robinson , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klünder , Wen Zhou
IPC: A61K31/4985 , A61K31/495 , A61P1/00 , A61K9/00 , A61K9/48
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
-
公开(公告)号:US20220273651A1
公开(公告)日:2022-09-01
申请号:US17732070
申请日:2022-04-28
Applicant: AbbVie Inc.
Inventor: Aileen L. Pangan , Roopal B. Thakkar , Steven Jungerwirth , Ana Paula Machado De Lacerda , Anne M. Robinson , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klünder
IPC: A61K31/4985 , A61K31/495 , A61P1/00 , A61K9/00 , A61K9/48
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
-
公开(公告)号:US20210361647A1
公开(公告)日:2021-11-25
申请号:US17115833
申请日:2020-12-09
Applicant: AbbVie Inc.
Inventor: Roopal B. Thakkar , Steven Jungerwirth , Ana Paula Machado de Lacerda , Ann M. Robinson , Jose Jeffrey V. Enejosa , Aileen L. Pangan , Mohamed-Eslam F. Mohamed , Ahmed A. Othman , Ben Klunder , Ayman D. Allian
IPC: A61K31/4985 , A61K31/495 , A61P1/00 , A61K9/00 , A61K9/48
Abstract: The present disclosure is directed to methods for treating Crohn's disease, and in particular, to methods for inducing clinical remission and/or endoscopic improvement of Crohn's disease, using a JAK1 inhibitor. In certain embodiments, the patient is administered an induction dose of the JAK1 inhibitor to induce clinical remission and/or endoscopic improvement of the Crohn's disease, followed by administration of at least one maintenance dose of the JAK1 inhibitor thereafter. In other embodiments, the present disclosure is directed to methods for treating ulcerative colitis using a JAK1 inhibitor.
-
-